PerkinElmer (NYSE: PKI) announced Wednesday that it will acquire Signature Genomic Laboratories in a move to strengthen its genetic testing services, according to Associated Press.
Financial terms of the deal, which is expected to close next month, were not disclosed.
PerkinElmer said Signature will help expand its position in the molecular diagnostics market and strengthen its cancer diagnostics.
Top Best Penny Stocks, a leading financial publication, is pleased to alert investors of stocks on the move. Sign up for our Free Stock Newsletter.
PerkinElmer Inc. said it employs about 8,500 people and has customers in more than 150 countries. Earlier this year, the company acquired the remaining 50 percent of a joint venture with Danaher Corp. (NYSE: DHR).
Danaher initially entered the joint-venture as part of its purchase of the analytical technologies business of MDS Inc. (NYSE: MDZ).
Sign up for Top Best Penny Stocks' free newsletter. To subscribe, enter your e-mail address into the frame at the bottom of this press release or visit our website.
Follow us on Twitter: http://www.Twitter.com/topbestps
About Us
Top Best Penny Stocks is a leading stock web site that allows investors and interested parties to research stocks that are on the move. We also track small cap companies that are on the brink of a financial breakout. To feature a company on our web site please contact us at the email listed below.
Please click here to read the full disclaimer.
